Home › Compare › LOBEF vs GBDC

LOBEF vs GBDC: Dividend Comparison 2026

LOBEF yields 3861.00% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LOBEF wins by $5102776617519.15M in total portfolio value
10 years
LOBEF
LOBEF
● Live price
3861.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5102776617540.00M
Annual income
$4,855,397,881,919,778,000.00
Full LOBEF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — LOBEF vs GBDC

📍 LOBEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLOBEFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LOBEF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LOBEF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LOBEF
Annual income on $10K today (after 15% tax)
$328,185.33/yr
After 10yr DRIP, annual income (after tax)
$4,127,088,199,631,811,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, LOBEF beats the other by $4,127,088,199,617,828,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LOBEF + GBDC for your $10,000?

LOBEF: 50%GBDC: 50%
100% GBDC50/50100% LOBEF
Portfolio after 10yr
$2551388308780.43M
Annual income
$2,427,698,940,968,114,000.00/yr
Blended yield
95.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

LOBEF
No analyst data
Altman Z
-9.3
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LOBEF buys
0
GBDC buys
0
No recent congressional trades found for LOBEF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLOBEFGBDC
Forward yield3861.00% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$5102776617540.00M ✓$20.85M
Annual income after 10y$4,855,397,881,919,778,000.00 ✓$16,450,733.83
Total dividends collected$5085877075297.57M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: LOBEF vs GBDC ($10,000, DRIP)

YearLOBEF PortfolioLOBEF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$396,800$386,100.39$12,492$1,791.70+$384.3K → LOBEF
2$14,742,780$14,318,203.95$16,527$3,160.58+$14.73M → LOBEF
3$512,952,973$497,178,198.17$23,588$5,904.90+$512.93M → LOBEF
4$16,715,748,598$16,166,888,916.48$37,141$11,901.65+$16715.71M → LOBEF
5$510,255,139,456$492,369,288,456.53$66,205$26,463.38+$510255.07M → LOBEF
6$14,592,492,784,652$14,046,519,785,434.00$137,452$66,612.65+$14592492.65M → LOBEF
7$391,042,310,644,499$375,428,343,364,921.60$342,372$195,298.53+$391042310.30M → LOBEF
8$9,820,789,713,309,148$9,402,374,440,919,534.00$1,053,292$686,954.33+$9820789712.26M → LOBEF
9$231,195,080,018,900,830$220,686,835,025,660,030.00$4,111,439$2,984,416.95+$231195080014.79M → LOBEF
10$5,102,776,617,540,002,000$4,855,397,881,919,778,000.00$20,849,974$16,450,733.83+$5102776617519.15M → LOBEF

LOBEF vs GBDC: Complete Analysis 2026

LOBEF — Stock

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.

Full LOBEF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this LOBEF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LOBEF vs SCHDLOBEF vs JEPILOBEF vs OLOBEF vs KOLOBEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.